VIR Vir Biotechnology, Inc. Insider Trading

CEO De Backer sells 72,559 VIR shares at $9.16; retains 948,145 shares amid $-163.1M net loss and -7.6% annual revenue decline

De Backer Marianne (President and CEO) sold 72,559 shares at $9.16 on 2026-04-06, reducing her position by 7.1% from 1,020,704 to 948,145 shares and raising $664,350.20. The sale occurred near the 52-week high of $10.00 and within the stock's 52-week range of $4.28–$10.00. Fundamental context shows the company posted net income of $-163,141,000.00 in the latest full fiscal year and reported annual revenue growth of -7.6%, with most recent quarterly revenue at $240,000.00, indicating operational strain. Her prior sale at this ticker in April 2024 returned +9.9% over 30 days and -6.4% over 90 days, establishing a pattern where 100.00% of her prior sells across all tickers were well-timed at the 90-day mark (stock fell after exit), though this represents only 1 observed same-ticker trade point.

SVF Endurance sells 191.9K VIR shares at $5.98; stock now $6.27, down 49.8% from 52-week high.

SVF Endurance, a 10% owner in Vir Biotechnology, sold 191,854 shares at $5.98 on 2025-12-01, reducing holdings by 1.4% from 13.92M to 13.73M shares. The sale occurred when VIR was trading -49.8% below its 52-week high of $12.48, near the lower end of the $4.28–$12.48 range. This follows an unusually active selling pattern: four additional sales at VIR occurred in the preceding days (2025-11-28, 2025-11-26, 2025-11-25, 2025-11-24), suggesting sustained liquidation. Against the cross-ticker track record showing a 100.00% well-timed rate on 20 prior sells with an average 90-day return of -61.9%, this VIR-specific selling occurs against a backdrop of fundamental weakness: the company posted a quarterly revenue of $240,000.00, annual revenue decline of -13.9%, and a full-year net loss of $-163,141,000.00. The stock has rebounded +12.0% in 30 days and +22.0% in 90 days since the initial transaction date, indicating near-term price recovery that post-dates the sale.

SVF Endurance sells 189,431 VIR shares (189.4K) for $1.2M; 10% holder reduces stake by 1.3% at $6.41 blended price

SVF Endurance, a 10% owner of Vir Biotechnology, executed two separate sales totaling 189,431 shares for $1,213,666.68 on 2025-11-26 and 2025-11-28 at a blended average price of $6.41, reducing holdings from 14.11M to 13.92M shares. The sales occurred as the stock trades at $6.07, down 51.4% from its 52-week high of $12.48, despite a 21.4% gain over the prior 90 days. Vir's fundamentals show Revenue of $240,000.00 in the latest quarter, a net loss of $-163,141,000.00, and annual revenue decline of -13.9%, with the company unprofitable over its most recent full fiscal year. The insider's cross-ticker track record shows 20 prior sells with a 100.00% 90-day well-timed rate, but at this specific ticker Vir, prior outcomes remain largely unmeasurable; the two most recent same-ticker sales (2025-10-22 and 2025-10-23) showed 30-day declines of -7.7% and -5.2% respectively.

SVF Endurance sells 463,774 VIR shares for $2.9M at $6.27 avg; holds 14.11M post-sale amid unprofitable operations.

SVF Endurance (10% Owner) filed a Form 4 disclosing 2 separate sales on 2025-11-24 and 2025-11-25, totaling 463,774 shares for $2,906,278.41 at a blended average price of $6.27, reducing holdings from 14,573,983 to 14,110,209 shares (-3.2%). This sale occurred as the stock trades at $6.39 (current), down -48.8% from its 52-week high of $12.48, though up +3.2% over 30 days and +26.8% over 90 days. Fundamentally, the company posted a net loss of $163,141,000 in its latest quarter, revenue of $240,000.00, annual revenue decline of -13.9%, and operates as an unprofitable entity on a full-year basis with a market cap of $889,008,954.48. Reviewing SVF Endurance's prior VIR trades (5 sell transactions from October–November 2025), the most recent measurable outcome at 30 days showed -5.2% (October 23 sale), while earlier October sales (21st, 22nd, 20th) registered -11.8%, -7.7%, and -12.3% 30-day returns respectively, with none yet measurable at the 90-day horizon. Across the insider's broader cross-ticker history (20 prior sells), the average 90-day return is -61.3% with a well-timed rate of 100.00%, indicating the insider's sell pattern has historically preceded declines; however, that track record does not yet extend to this ticker's outcome since the current transaction is freshly filed.

SVF Endurance (Cayman) Ltd sells 298,649 shares of VIR in 2 transactions for $1.8M; 10% holder maintains 14.71M shares post-sale.

SVF Endurance executed 2 separate sales totaling 298,649 shares for $1,812,377.56 at blended average price $6.07, reducing its stake by 2.0% to 14.71M shares. The sales occurred on 2025-10-22 and 2025-10-23 at $6.15 and $5.99 respectively, in a period when VIR is trading 52.1% below its 52-week high of $12.48 and the stock has risen 13.7% over the prior 30 days. SVF Endurance's cross-ticker track record shows a 100% well-timed rate on 20 prior open-market sales with average 90-day return of -59.9%, but this timing metric is not applicable to the current ticker-specific context: at VIR specifically, the insider has executed 5 prior sells (2025-10-21, 2025-10-20, 2025-10-10, 2025-10-09, 2025-10-08) with 0 measurable outcomes at the 90-day horizon. The company remains unprofitable with net income of $-110,958,000.00 for the latest fiscal year and annual revenue growth of -13.9%, indicating deteriorating fundamentals independent of timing considerations.

SVF Endurance sold 330,210 shares for $2,058,247.33 at $6.20–$6.30 as stock trades 51% below 52-week high; cross-ticker track record shows 100.00% well-timed sales.

SVF Endurance (10% Owner) executed 2 separate sales totaling 330,210 shares for $2,058,247.33 on October 20–21, selling at prices ranging from $6.20 to $6.30, which represent a blended average price of $6.23. The stock currently trades at $6.12, down 51.0% from its 52-week high of $12.48, and the insider's holdings decreased by 2.2% (from 15.34M to 15.01M shares), indicating a relatively modest reduction in exposure. Across the insider's cross-ticker history, 20 prior sells show a well-timed rate of 100.00% (with an average 90-day return of -59.4%), demonstrating a strong pattern of selling before subsequent declines. However, at VIR specifically, 5 prior sales in October show no yet-measurable 30- and 90-day outcomes, so performance data cannot yet be assessed at this ticker. The company remains unprofitable with net income of $-110,958,000.00 and annual revenue contraction of -13.9%, providing fundamental context for insider reduction activity, though the modest share reduction and timing relative to the recent 16.1% 30-day recovery suggest limited urgency.

SVF Endurance sells 251,360 VIR shares for $1.5M after 5 rapid sales in 3 days; stock down 54.2% from high.

SVF Endurance (Cayman) Ltd, a 10% owner of Vir Biotechnology, executed 2 separate sales totaling 251,360 shares for $1,543,898.73 on October 9–10, 2025, at a blended average price of $6.14, reducing holdings by 1.6% to 15.37M shares. This filing is part of a concentrated selling sequence: the SAME-TICKER HISTORY section documents 4 additional sales at this ticker on October 8, 7, 6, and 3, indicating deliberate systematic disposition. The current price of $5.72 is 54.2% below the 52-week high of $12.48, and the company is deeply unprofitable (net income of $-110,958,000.00 in the latest period) with negative annual revenue growth of -13.9%. While the insider's cross-ticker track record shows a 100.00% well-timed rate at the 90-day mark with an average 90d return of -57.8% following sells, this pattern has not yet been established at the VIR ticker itself—the prior measurable trade (June 29, 2023) was indeed well-timed with a 90d return of -63.2%, but the five most recent VIR trades remain unmeasured. The rapid and sustained selling by a 10% owner during a steep stock decline warrants investor attention to the company's operational and financial trajectory.

SVF Endurance (10% owner) sells 538,375 shares in 2 transactions at blended $5.99 amid -51.6% decline from 52-week high; cross-ticker track record 100% well-timed at 90d

SVF Endurance, a 10% owner, executed 2 separate sales totaling 538,375 shares (538.4K shares) for $3,223,938.98 ($3.2M) on October 7-8, 2025, at a blended average price of $5.99, reducing holdings by 3.3% from 16.16M to 15.62M shares. VIR is currently trading at $6.04, -51.6% from its 52-week high of $12.48, and the company reported a $-111.0M net loss with -13.9% annual revenue decline. The filer's cross-ticker track record shows a 100% well-timed rate at the 90-day mark across 20 prior sells (avg 90d return -57.4%), meaning this insider's historical sales preceded stock declines. At VIR specifically, 2 prior measurable sells in June 2023 posted 90-day returns of -63.2% and -63.1%, continuing this pattern of sales preceding material downside.

Major shareholder SVF Endurance sells 524,297 shares (524.3K) for $2.9M at blended $5.57, -54.6% from 52-week high

SVF Endurance (Cayman) Ltd, a 10% owner, executed 2 separate sales totaling 524,297 shares for $2,922,426.16, reducing holdings by 3.1%. The sales occurred at $5.56 and $5.69 on October 3 and 6, 2025, well below the 52-week high of $12.48 and shortly after a 7.4% 30-day rally. The company's fundamentals remain challenged: latest quarterly revenue was $1,214,000.00 with a net loss of $-110,958,000.00, and annual revenue declined 13.9% year-over-year. Notably, SVF's prior 4 measurable sales at VIR (June 2023) were all well-timed at the 90-day mark (each showing -43.7% to -63.2% 90-day returns), and the insider's cross-ticker track record shows 100.00% well-timed rate on 20 prior sells with -56.9% average 90-day return, suggesting a consistent pattern of selling before subsequent declines across holdings.